An experimental drug called KCL-286 has shown the ability to repair DNA damage and reduce inflammation in mice, according to researchers at King’s College London.
The FDA launched the Neuroscience Advancement and Innovation Nexus to accelerate medical product development for brain conditions, starting with Alzheimer’s prevention.
The FDA announced the Rare Disease Framework Initiative to create a tailored regulatory approach for rare disease drug development, aiming to accelerate treatments for small patient populations.
